Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Amyloid precursor-like protein 2 (APLP2) has been previously associated with pro-tumor phenotypes in cancer cells, and in this current study we investigated the expression and functions of this protein in macrophages. Our findings showed that APLP2 expression was increased in monocyte-like U937 cells after cytokine-induced differentiation to macrophage-like cells. Evaluation of human mRNA data revealed that APLP2 is more highly expressed in human M2/anti-inflammatory (pro-tumor) macrophages than in M1 macrophages (which have a pro-inflammatory, anti-tumor phenotype). Consistent with the mRNA data, by immunoblotting we identified increased APLP2 protein expression in mouse M2/anti-inflammatory macrophages. Intratumoral infiltration of M2/anti-inflammatory macrophages has been reported in several cancers, including neuroblastoma (NB). We observed that treatment of macrophages with NB-conditioned media induced M2/anti-inflammatory and mixed phenotypes. Through comparison of macrophages from wild-type and APLP2-knockout mice, we correlated alterations in inflammation-associated markers with the presence of APLP2. This suggests that APLP2 influences macrophage polarization dynamics between M0/unpolarized and pro- and anti-inflammatory states, and populations altered by APLP2 KO resemble the macrophage profiles altered with NB-conditioned media treatment. In total, our work implicates APLP2 as a mediator of macrophage status, namely in the M0/unpolarized macrophage and the M1/pro-inflammatory and M2/anti-inflammatory axis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011594 | PMC |
| http://dx.doi.org/10.3389/fonc.2025.1570955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloid precursor-like protein 2 expression in macrophages: differentiation and M1/M2 macrophage dynamics.
Front Oncol
April 2025
Eppley Institute, University of Nebraska Medical Center, Omaha, NE, United States.
Amyloid precursor-like protein 2 (APLP2) has been previously associated with pro-tumor phenotypes in cancer cells, and in this current study we investigated the expression and functions of this protein in macrophages. Our findings showed that APLP2 expression was increased in monocyte-like U937 cells after cytokine-induced differentiation to macrophage-like cells. Evaluation of human mRNA data revealed that APLP2 is more highly expressed in human M2/anti-inflammatory (pro-tumor) macrophages than in M1 macrophages (which have a pro-inflammatory, anti-tumor phenotype).
View Article and Find Full Text PDFProteomic analysis indicates lower abundance of platelet α-granule proteins in Glanzmann thrombasthenia.
J Thromb Haemost
July 2025
Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address:
Background: Glanzmann thrombasthenia (GT) is an inherited platelet function disorder caused by mutations in the fibrinogen receptor αβ. The deficiency can be quantitative (type I/II) or qualitative (type III). It causes lack of platelet aggregation and leads to a moderate to severe bleeding tendency.
View Article and Find Full Text PDFAssessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.
Mov Disord
May 2025
Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China.
Background: Amyloid precursor-like protein 1 (APLP1) is involved in pathological α-synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.
Objective: This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.
Methods: Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts.
Blood-derived APLP1 extracellular vesicles are potential biomarkers for the early diagnosis of brain diseases.
Sci Adv
January 2025
Department of Biotechnology, College of Life Science, CHA University, Gyeonggi-do 13488, Republic of Korea.
Article Synopsis
- Early detection of neurodegenerative diseases relies on identifying brain-specific biomolecules in blood, and this study explores amyloid precursor-like protein 1 (APLP1) as a new biomarker found in extracellular vesicles (EVs).
- The research confirms that APLP1 EVs in human blood come from the brain, supported by distinct small RNA patterns and the expression of miRNA targets that are highly present in brain tissue.
- Validation using special mouse models (Thy-1 GFP M line) alongside data analysis highlights APLP1 EVs' potential as both diagnostic markers and key players in advancing neurodegenerative disease diagnosis.
Familial Alzheimer's disease mutations in amyloid precursor protein impair calcineurin signaling to NMDA receptors.
J Biol Chem
February 2025
Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, The University of Tennessee Health Science Center, Memphis, USA. Electronic address:
Familial Alzheimer's disease (FAD) is frequently associated with mutations in the amyloid precursor protein (APP), which are thought to lead to cognitive deficits by impairing NMDA receptor (NMDAR)-dependent forms of synaptic plasticity. Given the reliance of synaptic plasticity on NMDAR-mediated Ca entry, shaping of NMDAR activity by APP and/or its disease-causing variants could provide a basis for understanding synaptic plasticity impairments associated with FAD. A region of APP (residues 639-644 within APP695) processed by the γ-secretase complex, which generates amyloid-β peptides, is a hotspot for FAD mutations.
View Article and Find Full Text PDF